IndexProtamine 57
Protection
devices, distal embolic 128–9
myocardial 138–9
Protein, myosin binding 238, 240
Proteinuria 211–2
Pseudomonas 318, 323, 329
Pseudoaneurysms 316
PTCA 135–6, 143, 150
Pulmonary arterial hypertension 282
Pulse volume recording 182–3
PURSUIT 32
PVCs 274–5, 282, 289
Pyrexia 259
Questionnaire, Rose 171
Quinapril 227
Quinidine 250, 268, 287, 290
Radiation 340, 342
Radiculopathy 174
Radiofrequency Ablation in Paroxysmal Atrial Fibrillation
254
Radionuclide ventriculography 301
Ramipril 227
Randomized Evaluation of Long Term Anticoagulant
Therapy trial 254
Receptor, angiotensin 291
Recommendations for Blood Pressure Measurement in
Humans and Experimental Animals 196, 200
Regurgitation 294, 299–300, 309–10, 326
aortic 282, 294–6, 299, 301
mitral 281, 302–9, 311
valvular 296, 313–4
Rehabilitation, cardiac 44, 87
RELY trial 254
Renal failure, chronic 169, 182, 189, 192
Renin-angiotensin-aldosterone system 42, 64, 68,
114–5
Renovascular disease 202
Reoperation 139, 142, 144, 151
Reserve, vasodilatory 129
Respiratory gas exchange, measuring 225
Response
hemodynamic 300–3
ventricular 245–6, 250
Restenosis 129, 132
Resuscitation 291
Resuvastatin 190
Resynchronization, cardiac 233
Reteplase 57
Retinoids 192
Retinopathy 202
Revascularization 11, 21–3, 25–6, 37, 39–40, 57, 72, 78,
122, 124, 128, 136–7, 139, 143, 145, 149–51, 153,
158, 160, 167–9, 172, 177, 179–82, 184–6, 225,
231–2, 248, 277–8, 283, 338
percutaneous 24
Rheumatic disease 282
Rhythm, idioventricular 73
Rickettsia 241
Rifampin 321, 327–8
Right ventricular infarction. See Infarction, RV
Risk
absolute 219, 221, 246
assessment 187–9, 194–5, 284–5, 337
Framingham 198, 202, 205, 214–5, 338
Reynolds 214
atherosclerotic 187
CAD 338–9, 343
cardiac 153–7, 160–1
cardiovascular 165–6, 168–9, 173, 180, 186, 197–202,
206, 210, 340, 343
categories 188–9
clinical 153–6, 158, 161
CV 227
CVD “lifetime” 214, 221
embolization 326
factors 140, 142–3, 247, 249, 253, 273, 284–5, 291
high 339
ischemic 154–5
management 188, 194
neurologic 138
noncardiac 158
operative 141, 144
perioperative 153–4
prediction 338
predictors 291
procedural 142
profi le 187
ratio 337
reduction 191
relative, early invasive vs. conservative therapies 38
stratifi cation 11, 13, 31, 38–39, 81, 136, 275, 287, 342
cardiac 157
post MI 291
stroke 134, 138, 144
Rivaroxaban 254
Rocky Mountain spotted fever 241
Romano–Ward syndrome 239
Root, aortic 300–2
Roth’s spots 314
Rupture
free wall 69, 71, 149
papillary muscle 69, 71
postinfarction ventricular septal 149